VitaSpring Biomedical Co. Ltd.

Equities

VSBC

US92851B1026

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:03:41 2023-08-11 pm EDT			5-day change	1st Jan Change
15 ^USD	+36.24%		-.--%	-.--%

2022	VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	CI
2022	VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	CI

Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2020

September 28, 2020 at 09:22 am EDT

VitaSpring Biomedical Co. Ltd. announced earnings results for the second quarter ended July 31, 2020. For the second quarter, the company announced sales was USD 0 compared to USD 3,975 a year ago. Operating loss was USD 90,615 compared to operating Income of USD 762 a year ago. Net loss was USD 90,615 compared to net income of USD 762 a year ago. For the half year, sales was USD 0 compared to USD 11,190 a year ago. Operating loss was USD 108,360 compared to USD 7,747 a year ago. Net loss was USD 108,360 compared to USD 7,747 a year ago.

Latest news about VitaSpring Biomedical Co. Ltd.

VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	22-12-21	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	22-09-15	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2022	22-06-15	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2022	22-05-03	CI
VitaSpring Biomedical Co. Ltd. Auditor Raises 'Going Concern' Doubt	22-05-02	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021	21-12-23	CI
QuantuMDx Group Limited announced that it has received ?15 million in funding from VitaSpring Biomedical Co. Ltd.	21-11-06	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2021	21-09-15	CI
Vitaspring Biomedical Co. Ltd. Announces Management Changes	21-08-11	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2021	21-06-14	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2021	21-04-14	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter Ended October 31, 2020	20-12-15	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2020	20-09-28	CI
VitaSpring Biomedical Co. Ltd. announced that it expects to receive $0.082342 million in funding	20-07-13	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2020	20-06-19	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2020	20-06-09	CI
SHEMN CORP will Change its Name to VitaSpring Biomedical Co. Ltd	20-04-21	CI
VitaSpring Biomedical Co. Ltd. will Change its Ticker to VSBC from SHNC	20-04-21	CI
Shemn Corp. Announces Management Changes	20-02-26	CI
Shemn Corp. Announces Management Changes	20-01-31	CI
Shemn Corp. Reports Earnings Results for the Third Quarter Ended October 31, 2019	19-12-12	CI
Shemn Corp. Reports Earnings Results for the Second Quarter Ended July 31, 2019	19-08-27	CI
Shemn Corp. Reports Earnings Results for the First Quarter Ended April 30, 2019	19-06-03	CI
Shemn Corp. Announces Executive Changes	19-04-17	CI
VitaSpring Biomedical Co. Ltd. has completed an IPO.	17-12-04	CI

Chart VitaSpring Biomedical Co. Ltd.

Duration

Period

More charts

Company Profile

Vitaspring Biomedical Co. Ltd. is focused on cell medical industry. The Company is engaged in the business of developing and marketing products that promote wellness and a healthy lifestyle. The Company invests in research and development of stem cell applications in regenerative medicine, establish advanced medical research centers and cell production centers and provides GTP standard stem cell preparations for the development of cellular drugs. The Company is focused on the fields of medicine, preventive health care, beauty, and anti-aging. It is also focused on developing X.MSC cytopharmaceuticals.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VITASPRING BIOMEDICAL CO. LTD.	-.--%	3.11B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs